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Abstract
Background: Cholesterol gallstone disease (GS) is highly prevalent among Hispanics and
American Indians. In GS, the pool of bile acids (BA) is decreased, suggesting that BA absorption is
impaired. In Caucasian GS patients, mRNA levels for ileal BA transporters are decreased. We
aimed to determine fecal BA excretion rates, mRNA levels for ileal BA transporter genes and of
regulatory genes of BA synthesis in Hispanic GS patients.
Results: Excretion of fecal BA was measured in seven GS females and in ten GS-free individuals,
all with a body mass index < 29. Participants ingested the stool marker Cr2O3 (300 mg/day) for 10
days, and fecal specimens were collected on the last 3 days. Chromium was measured by a
colorimetric method, and BA was quantitated by gas chromatography/mass spectroscopy. Intake
of calories, nutrients, fiber and cholesterol were similar in the GS and GS-free subjects. Mean BA
excretion levels were 520 ± 80 mg/day for the GS-free group, and 461 ± 105 mg/day for the GS
group. Messenger RNA expression levels were determined by RT-PCR on biopsy samples obtained
from ileum during diagnostic colonoscopy (14 GS-free controls and 16 GS patients) and from liver
during surgery performed at 8 and 10 AM (12 GS and 10 GS-free patients operated on for
gastrointestinal malignancies), all with a body mass index < 29. Messenger RNA level of the BA
transporter genes for ileal lipid binding protein, multidrug resistance-associated protein 3, organic
solute transporter alpha, and organic solute transporter beta were similar in GS and GS-free
subjects. Messenger RNA level of Cyp27A1, encoding the enzyme 27α-hydroxylase, the short
heterodimer partner and farnesoid X receptor remained unchanged, whereas the mRNA level of
Cyp7A1, the rate limiting step of BA synthesis, was increased more than 400% (p < 0.01) in the
liver of GS compared to GS-free subjects.
Conclusion: Hispanics with GS have fecal BA excretion rates and mRNA levels of genes for ileal
BA transporters that are similar to GS-free subjects. However, mRNA expression levels of Cyp7A1
are increased in GS, indicating that regulation of BA synthesis is abnormal in Hispanics with GS.
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Cholesterol gallstone disease (GS) is prevalent worldwide,
and is endemic among American Indians and Hispanics
[1,2]. In GS, the primary abnormality is secretion by the
liver into the gallbladder of bile that is supersaturated
with cholesterol. This leads to precipitation of cholesterol
and formation of gallstones. The most common causes of
cholesterol-saturated bile are a decrease in the bile acid
(BA) pool and secretion rate and an increase in cholesterol
output into the bile [3,4]. Thus, one current hypothesis
about the primary cause of GS is abnormal regulation of
cholesterol and BA metabolism.
Fecal BA excretion rate is a marker of daily BA synthesis,
and is higher in Argentinean Hispanic patients with GS
than in GS-free individuals [5]. Similarly, BA synthesis,
indirectly assessed by the measurement of serum 7α-
hydroxy-4-cholesten-3-one concentration in one point in
time, was found increased in Chilean Hispanics with GS
compared to GS-free individuals, suggesting increase BA
synthesis in GS [6,7]. Similar results were observed in
Caucasian individuals [8,9]. Consistent with these find-
ings, the mRNA levels of BA transporter genes are
decreased in the ileum of female Caucasian GS patients,
supporting the hypothesis that absorption of BA is
impaired and fecal BA excretion is increased in subsets of
GS patients [10,11]. GS-free North American Indians, a
population with an extremely high prevalence of GS, also
have higher fecal BA excretion rates than non-Indian sub-
jects [12]. However, GS patients who are North American
Indians [12] or obese non-Indians [13] have fecal BA
excretion levels that are similar compared to levels found
in GS-free subjects. Consistent with these findings, other
studies performed among Italian [14] and Chinese [15]
subjects have shown unchanged mRNA expression levels
of CYP7A1, the ratelimiting enzyme of BA synthesis.
These apparent discrepancies might be because the mech-
anisms of GS formation are different in patients with dif-
ferent ethnic backgrounds, or because indirect assessment
of BA synthesis in one part of the day might not reflect
total daily production of BA, as occurs with the measure-
ment of daily fecal BA excretion. Thus, the objective of this
study was to quantitate daily fecal BA excretion rates,
mRNA expression levels of ileal BA transporters and of
hepatic regulatory genes of BA synthesis, in GS patients
from a high-risk Hispanic population.
Results
Nutrients and caloric intake were similar in GS-free con-
trol subjects and GS patients in this study of fecal BA
excretion (results not shown). Caloric intake varied from
1220 to 2237 Kcals/day for all subjects. Fiber intake varied
between 19.3 and 24.1 g/day, and cholesterol intake var-
ied between 94.4 and 281.3 mg/day, and both were simi-
lar in GS-free and GS patients. All subjects were non-obese
and had similar values for age, body mass index (BMI)
and serum lipids (Table 1). No significant differences
were observed in daily fecal BA excretion rates between
the GS-free and GS patient groups, with rates varying from
186 ± 53 (mean ± standard error) and 883 ± 53 mg/day in
the GS-free patients, and from 120 ± 17 and 897 ± 157
mg/day in the GS group (Table 1).
The mRNA levels of genes involved in the regulation of
the enterohepatic circulation of BA in the ileum were ana-
lyzed in GS and GS-free subjects with similar average ages
and BMIs. Histological analysis of ileal biopsies showed
no abnormalities for either GS-free or GS patients. As
shown in Table 2, no differences were observed between
GS patients and GS-free subjects in the mRNA levels of BA
transporter genes, including the apical sodium dependent
bile acid transporter (Astb); Fabp6, which is the gene for
ileal lipid binding protein (ILBP); Abcc3, which is the gene
for multidrug resistance-associated protein 3 (MRP3); or
Ost  and Ost , which are the genes for the organic solute
transporters alpha and beta. Similarly, no changes were
seen in the expression levels of FGF19, the ileal hormone
that regulates BA synthesis.
The mRNA levels of regulatory genes of BA synthesis were
determined in liver biopsies obtained from a series of GS
and GS-free subjects subjected to laparotomy for GS, or
for localized gastrointestinal malignancies, respectively.
Histological analysis of liver biopsies was normal for
either GS-free or GS patients. As shown in Table 3, the
mRNA level of Cyp7A1, the gene encoding 7α-hydroxy-
lase, the rate limiting step of BA synthesis, was increased
by >400% (p < 0.01) in GS compared to GS-free patients.
No differences were observed between GS patients and
GS-free subjects in the mRNA levels of Cyp27A1 and of
regulatory genes of BA synthesis, including Nr0B2 (short
heterodimer partner) and Nr1H4 (farnesoid X receptor,
FXR).
Discussion
This study found similar rates of daily BA excretion in the
feces of Chilean Hispanic GS patients and GS-free individ-
uals. Our observations do not support the results of
Mamianetti et al., who found increased BA excretion lev-
els in the feces of GS patients compared to GS-free subjects
[5]. However, since that study was performed without a
fecal marker to correct for fecal flow, its findings are diffi-
cult to interpret, and cannot be compared to our study
and other similar studies in which fecal flow markers were
used to assess sterol excretion and balance [16-18]. Other
studies that have reported fecal BA excretion rates in GS
patients show similar daily rates of BA excretion in the
feces of GS and GS-free subjects [12,13].Page 2 of 6
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excretion in GS patients, we found that GS-free and GS
patients had similar mRNA levels for BA transporter genes
in the ileum. This observation suggested that this group of
GS patients had no abnormalities in ileal BA absorption,
in contrast with the decreased mRNA levels of BA trans-
porters observed in the ileum of Caucasian female GS
patients in other studies [10,11]. Our results indicate that
Chilean Hispanics with GS maintain a normal rate of BA
absorption in the ileum. However, a specific abnormality
in the expression levels of ileal BA transporters in GS
patients may not be detected in this population because of
Table 1: Age, BMI, serum lipids and fecal BA excretion in control and GS patients.
Serum lipid concentration (mg/dl)
Subjects Age (y) BMI Total CH HDL TG Fecal BA (mg/day)
GS-free
1 48 23.4 170 52 99 883 ± 53
2 43 23.4 223 46 73 824 ± 68
3 46 22.2 219 59 220 418 ± 140
4 36 23.7 219 67 57 880 ± 150
5 22 28.3 194 58 81 250 ± 54
6 48 22.1 226 76 68 428 ± 140
7 34 22.4 153 60 38 420 ± 127
8 36 26.3 192 50 100 403 ± 140
9 37 24.1 158 37 111 186 ± 30
10 55 23.0 247 66 104 508 ± 250
Mean ± SE 41 ± 3 24.1 ± 0.6 198 ± 10 57 ± 4 95 ± 16 520 ± 80
With gallstones
11 55 23.8 247 66 104 374 ± 9
12 51 22.5 163 50 65 576 ± 250
13 30 22.5 150 39 165 314 ± 86
Cholecystectomy
14 47 22.1 150 28 177 324 ± 46
15 53 22.0 148 50 118 120 ± 17
16 37 24.1 162 44 146 897 ± 157
17 30 26.7 150 39 165 538 ± 170
Total GS
Mean ± SE 47 ± 4 23.4 ± 0.6 158 ± 3 46 ± 4 114 ± 19 461 ± 105
Each individual value of fecal BA excretion represents the mean ± SE of the three days of fecal collection of each participant. Body weights were: 
GS-free subjects, 58.6 ± 1.9; GS patients, 55.3 ± 1.7. BMI was calculated as weight/height (kg/m2); CH, cholesterol; TG, triglycerides.
Table 2: Expression levels of mRNA of ileal transporters of BA 
and FGF19 in GS patients.
Gene symbol Gene ID Expression value in GS P value
Slc10A2 6555 0.99 ± 0.19 0.964
Fabp6 2172 1.01 ± 0.11 0.983
Abcc3 8714 1.08 ± 0.07 0.586
Ost 200931 1.18 ± 0.11 0.425
Ost 123264 1.02 ± 0.08 0.902
Fgf19 9965 1.30 ± 0.20 0.411
Expression represent the mean values ± SE of GS subjects. Expression 
values for GS-free subjects were assigned as 1.00. Participants of the 
study were: GS, n = 16 (16 GS, 12F/4 M and 7), GS-free subjects, n = 
14 (8 F/6 M). Age ranges were 62 ± 2 for GS-free, 57 ± 3 for GS. 
Gene ID corresponds to gene annotation obtained from NCBI web 
site. Expression of the following genes were determined: Slc10A2, 
ASBT (Apical sodium dependent bile acid transporter); Fabp6, ILBP 
(Ileal Lipid Binding protein); Abcc3, MRP3 (Multidrug resistance-
associated protein 3); Ost , Organic solute transporter alpha; Ost , 
Organic solute transporter beta; Fgf19, Fibroblast growth factor 19.
Table 3: mRNA expression levels of hepatic regulatory genes of 
BA synthesis in GS patients.
Gene symbol Gene ID Expression value ± SE p value
Cyp7A1 1581 4.12 ± 2.68 0.012*
Cyp27A1 1593 1.10 ± 0.45 0.717
Nr0B2 604630 1.08 ± 0.52 0.788
Nr1H4 603826 0.83 ± 0.28 0.523
Expression values represent the mean ± SE of GS subjects. Expression 
values for GS-free subjects were assigned as 1.00. Participants of the 
study were: GS, n = 12 (9 F/3 M), GS-free subjects, n = 10 (5 F/5 M). 
Age ranges were 50 ± 4 for GS and 56 ± 5 for GS-free. Gene ID 
corresponds to gene annotation obtained from NCBI. Cyp7A1, 
cytochrome P450, family 7, subfamily A, polypeptide 1 (cholesterol 
7α-hydroxylase); Cyp27A1, cytochrome P450, family 27, subfamily A, 
polypeptide 1 (sterol 27α-hydroxylase); Nr0B2 nuclear receptor 
subfamily 0, group B, member 2 (short heterodimer partner); Nr1H4, 
Nuclear receptor subfamily 0, group H, member 4 (farnesoid x 
receptor, FXR).Page 3 of 6
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who were used as both patients and controls in this study.
The finding that fecal BA excretion is unchanged in our GS
patients is consistent with normal rates of daily BA synthe-
sis determined by isotopic methods in GS [19,20] and
with normal mRNA expression levels of CYP7A1 found
among Italian [14] and Chinese [15] GS patients. These
observations apparently contradicts the finding of
increased mRNA levels of CYP7A1 of the present study
and the previously reported increase in 7α-hydroxy-4-
cholesten-3-one in serum in Hispanics [6,7], as well as in
Caucasian GS patients [8,9]. The most likely explanation
for this apparent contradiction is that the increased
CYP7A1 mRNA and serum 7α-hydroxy-4-cholesten-3-one
concentration seen in GS patients was observed at a single
time point, measured by an indirect assessment of BA syn-
thesis. Thus, the values may not reflect the daily rate of BA
synthesis as measured by the daily fecal BA excretion
method, or by isotopic methods. BA synthesis shows a
rapidly changing circadian rhythm in rodents [21] and in
humans [22]. Therefore, the increase in BA synthesis,
assessed by either CYP7A1 mRNA, or a serum marker of
BA synthesis measured at only one point during the day,
may indicate a secondary phenomenon that is an effect of
the loss of gallbladder function in some populations, and
not a primary pathogenic defect of all GS patients.
Whether the mechanism responsible for the increase
mRNA expression levels of CYP7A1 in GS is mediated by
the FXR nuclear receptor - dependent or FGF 19 - depend-
ent mechanism, cannot be elucidated with the results
obtained in these studies. It is possible that the fraction of
the BA pool stored in the intestine during the night is
higher in GS patients compared to GS-free subjects. This
situation could decrease BA concentration in hepatocytes
and consequently, decrease FXR activity followed by
increase of mRNA levels of CYP7A1 early in morning,
when liver biopsies and serum samples are obtained from
the subjects participating in these studies. Alternatively,
loss of gallbladder function because of the presence of
gallstones, or cholecystectomy could change the daily
secretion pattern of FGF19 with the subsequent modifica-
tion of the circadian rhythm of CYP7A1 mRNA.
The fecal BA excretion rates previously reported for North
American Indians are higher than rates observed for Cau-
casian individuals [12,16-18], but similar to the values
reported here. This suggests that Amerindians may have
higher rates of fecal BA excretion than other populations,
which might represent a common ethnic predisposition
to form gallstones, resulting from a reduced capacity for
BA absorption in the ileum. Another possibility relates to
the presence of common dietary constituents in the diet of
Amerindians and Hispanics that might increase fecal BA
excretion and cholesterol saturation in bile such as occurs
with legume diets [18,23], a common foodstuff in these
populations [23,24]. Specific types of fiber, such as the
saponin component in the soluble fraction of legumes,
may increase the synthesis of BA [25,26] and favour its
excretion in feces [18]. Interestingly, the levels of fecal BA
excretion reported here in GS patients and GS-free sub-
jects were similar to values reported for Caucasian subjects
ingesting a diet high in fiber [16] or in legumes [18].
Conclusion
Fecal BA excretion, a marker of daily BA synthesis, and
mRNA expression levels of ileal transporters remain
unchanged in GS compared to GS-free Hispanic subjects.
Increased CYP7A1 mRNA expression levels found in GS
compared to GS-free subjects, suggests that regulation of
BA synthesis is abnormal in GS patients from Hispanic
populations.
Methods
Patient selection and sample collection
The Institutional Review Board for Human Studies of the
Faculty of Medicine at the Pontificia Universidad Católica
de Chile approved this study, which was conducted
according to the 1975 Declaration of Helsinki. All subjects
participating in this study gave informed consent.
Daily excretion of fecal BA was measured in seven GS
female patients (3 with gallstones and 4 cholecystect-
omized), and in 10 GS-free female subjects. All partici-
pants worked at our institution as nurse assistants.
Gallstone disease was defined as either asymptomatic
cholelithiasis previously diagnosed by ultrasound, or
antecedent of cholecystectomy performed > 2 years prior
to the study. GS are mainly of the cholesterol type in the
Chilean population [2] and the morphology of patients's
gallstones was of the cholesterol type in this study [27].
Criteria for selection included: a) normal weight (BMI
<29); b) normal serum glucose, insulin and albumin con-
centrations; c) no antecedent of obesity or known changes
of > 5% in habitual body weight for 6 months prior to the
study; d) no antecedent of inflammatory bowel disease, or
diarrhea for 2 months prior to the study; d) no antecedent
of treatment with drugs affecting lipid metabolism. As a
stool marker of fecal flow, each subject ingested a capsule
containing 100 mg Cr2O3 (Merck, Darmstadt, Germany),
with the main meals, three times daily for ten days. Daily
fecal specimens were obtained for the last 3 days of the
study protocol, and stored at -20°C until processing. Sub-
jects ingested two daily meals at the Pontificia Universi-
dad Católica de Chile. Dietary energy, cholesterol, fat,
carbohydrate, protein and fiber were calculated from 7-
day dietary records using the software Food Processor 7.9
(ESHA Research, Oregon, USA).Page 4 of 6
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studies included subjects that had a BMI <29, normal
serum glucose, and no antecedent of treatment with drugs
affecting lipid metabolism, including thyroid hormones,
or drugs for treatment of inflammatory bowel disease. The
ileal biopsy study included 14 GS-free controls (8 female,
6 male), 16 GS subjects (9 with gallstones, 7 females, 2
males and 7 cholecystectomized, 5 females, 2 males), all
undergoing diagnostic colonoscopy for screening pur-
poses. Cholecystectomized patients had cholecystectomy
performed at least 3 years prior to colonoscopy. For each
patient, five to seven ileal biopsy specimens were
obtained from approximately 10 cm proximal to the ile-
ocecal valve in the ileal biopsy study. The experimental
protocol for the liver biopsy study included 12 GS patients
(9 female, 3 male), subjected to elective surgery because of
previously symptomatic GS and a control group formed
by 10 GS-free individuals (5 female, 5 male), operated
upon because of gastrointestinal cancer localized to the
affected organ. A liver biopsy was obtained at the begin-
ning of the surgical procedure.
A specimen of both the ileal and liver biopsy studies from
each individual were fixed and stained with hematoxylin-
eosin for histological analysis. All non-GS patients had a
normal abdominal ultrasound for assessment of GS.
Determination of fecal BA excretion
Fecal samples from three days of collection were subjected
to alkaline hydrolysis according to de Wael et al. [28].
Unconjugated BA was extracted into diethyl ether and
quantitated by gas chromatography/mass spectroscopy as
previously described [29,30]. Fecal chromium from the
ingested chromium oxide (Cr2O3) was determined
according to Calvert et al. [31]. Concentrations of chro-
mium and acidic sterols in feces 13 were calculated per
gram of fecal homogenate. The daily excretion of BA was
determined by the equation:
RNA extraction, reverse transcription and real-time PCR 
analysis
Total RNA was isolated from ileal biopsies by an acidic
guanidinium isothiocyanate/phenol/chloroform extrac-
tion procedure, as described by Chomczynski and Sacchi
[32]. Total RNA was reverse transcribed using the Super-
Script First-Strand Synthesis System for RT-PCR (Invitro-
gen, Bios Chile, I.G.S.A., Santiago, Chile) and random
hexamers. Quantitative polymerase chain reaction (PCR)
was performed in a Mx3000P Real-Time PCR System
(Stratagene, La Jolla, CA, USA) using Platinum Quantita-
tive PCR SuperMix-UDG (Invitrogen, Bios Chile, I.G.S.A.,
Santiago, Chile), and 25 ng of reverse transcribed RNA.
Specific TaqMan Gene Expression Assays (Applied Biosys-
tems, Foster City, CA) were performed for genes that reg-
ulate BA synthesis in the liver and BA absorption in the
ileum, and for eukaryotic 18S rRNA. The primers used in
the study are the following references from Applied Bio-
systems: Slc10A2, Hs00166561_m1; Fabp6, ILBP,
Hs00155029_m1; Abcc3, Hs 00358656_m1; Ost ,
Hs00380895_m1; Ost , Hs00418306_m1; Fgf19,
Hs00391591_m1; Cyp7A1, Hs 00167982_m1; Cyp27A1;
Hs00168003_m1; Nr0B2, Hs00222677_m1; Nr1H4,
Hs00231968_m1. Thermal cycling conditions were 95°C
for 10 minutes followed by 40 cycles at 93°C for 15 sec-
onds, and 60°C for 1 minute. Reactions were performed
in duplicate. Relative quantification of gene expression
was performed using the comparative threshold (Ct)
method as described by Applied Biosystems (Foster City,
CA, USA). Changes in mRNA expression level were calcu-
lated following normalization to 18S expression (Applied
Biosystems reference: Hs99999901_s1).
Statistics
Data are presented as mean ± standard error of the mean.
Statistical analysis was carried out by Student's t-test. The
Ct value obtained for control and GS samples was submit-
ted to a t-student analysis using REST-MCS software [33].
Differences were considered significant when p < 0.05.
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